

1 **Contrasting genomic epidemiology between sympatric *Plasmodium***
2 ***falciparum* and *Plasmodium vivax* populations**

3

4 Philipp Schwabl^{1,2*}, Flavia Camponovo^{3,4,5*}, Collette Clementson⁶, Angela M. Early², Margaret
5 Laws^{1,2}, David A. Forero-Peña⁷, Oscar Noya^{8,9}, María Eugenia Grillet¹⁰, Mathieu Vanhove^{1,2},
6 Frank Anthony⁶, Kashana James⁶, Narine Singh⁶, Horace Cox^{6,11}, Reza Niles-Robin⁶, Caroline
7 O. Buckee³, Daniel E. Neafsey^{1,2}

8

9 ¹ Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
10 Health, Boston, MA, USA

11 ² Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Cambridge,
12 MA, USA

13 ³ Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H.
14 Chan School of Public Health, Boston, MA, USA

15 ⁴ Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute,
16 Basel, Switzerland

17 ⁵ University of Basel, Basel, Switzerland

18 ⁶ National Malaria Program, Ministry of Health, Georgetown, Guyana

19 ⁷ Biomedical Research and Therapeutic Vaccines Institute, Ciudad Bolívar, Venezuela

20 ⁸ Institute of Tropical Medicine, Faculty of Medicine, Central University of Venezuela, Caracas,
21 Venezuela

22 ⁹ Center for Malaria Research, Institute of Higher Studies 'Dr. Arnaldo Gabaldon', Ministry of
23 People's Power for Health, Caracas, Venezuela

24 ¹⁰ Institute of Zoology and Tropical Ecology, Central University of Venezuela, Caracas,
25 Venezuela

26 ¹¹ Caribbean Public Health Agency, Port of Spain, Trinidad and Tobago

27

28 *equal contributions

29

30

31 **Keywords: *Plasmodium falciparum*; *Plasmodium vivax*; malaria; genomic epidemiology, Guyana**

32

33 **Abstract**

34 The malaria parasites *Plasmodium falciparum* and *Plasmodium vivax* differ in key biological
35 processes and associated clinical effects, but consequences on population-level transmission
36 dynamics are difficult to predict. This co-endemic malaria study from Guyana details important
37 epidemiological contrasts between the species by coupling population genomics (1,396
38 spatiotemporally-matched parasite genomes) with sociodemographic analysis (nationwide
39 patient census). We describe how *P. falciparum* forms large, interrelated subpopulations that
40 sporadically expand but generally exhibit restrained dispersal, whereby spatial distance and
41 patient travel statistics predict parasite identity-by-descent (IBD). Case bias towards working-
42 age adults is also strongly pronounced. *P. vivax* exhibits 46% higher average diversity (π) and
43 6.5x lower average IBD. It occupies a wider geographic range, without evidence for outbreak-
44 like expansions, only microgeographic patterns of isolation-by-distance, and weaker case bias
45 towards adults. Possible latency-relapse effects also manifest in various analyses. For example,
46 11.0% of patients diagnosed with *P. vivax* in Greater Georgetown report no recent travel to
47 endemic zones, and *P. vivax* clones recur in 11/46 patients incidentally sampled twice during
48 the study. Polyclonality rate is also 2.1x higher than in *P. falciparum*, does not trend positively
49 with estimated incidence, and correlates uniquely to selected demographics. We discuss
50 possible underlying mechanisms and implications for malaria control.

51

52 **Introduction**

53 Malaria caused by the parasite *Plasmodium falciparum* is responsible for more than half a
54 million deaths each year, predominantly in Sub-Saharan Africa and in children under five¹.

55 Malaria by *Plasmodium vivax* causes less acute mortality but is more widely distributed at the
56 global scale^{2,3} and likewise causes severe morbidity and socioeconomic impact¹.

57

58 Progress towards malaria elimination is currently stalling in many endemic regions⁴, and

59 divergent parasite species' responses to intervention play an important role⁵⁻⁹. *P. vivax* in
60 particular often shows stable or increasing incidence during periods in which co-endemic *P.*
61 *falciparum* is successfully being reduced⁴. It is therefore important to better understand how
62 epidemiological differences between the species affect the impact of control strategies and
63 whether species-tailored approaches are warranted in co-endemic settings.

64 *P. falciparum* and *P. vivax* are not closely related (current theory suggests 30-50 million years of
65 independent evolution^{10,11}) and differ in key developmental processes and associated clinical
66 effects⁴. For both species, human infection begins when sporozoites enter the skin and
67 vasculature during infected anopheline mosquito blood meal. The parasite first infects the liver
68 and later transitions to blood-stage infection where repeated erythrocyte invasion, intra-
69 erythrocytic replication, and erythrocyte rupture are associated with febrile and paroxysmal
70 disease. A subset of blood-stage parasites commit to onward transmission by differentiating into
71 the sexual, mosquito-infective gametocyte form. Meiosis occurs after transmission to the
72 mosquito via blood meal and involves outcrossing if genetically distinct gametocytes are present
73 (i.e., if the human infection is polyclonal). The parasite forms oocysts in the mosquito midgut
74 and then sporozoites, which accumulate in the mosquito salivary glands¹².

75 *P. vivax* behaves distinctly within the human stages of this infection cycle in multiple key
76 aspects. First, not all *P. vivax* parasites that successfully reach the liver immediately begin
77 schizogony, a process which begins immediately in all liver-stage *P. falciparum* parasites.
78 Rather, a subset of liver-stage *P. vivax* parasites form a dormant hypnozoite reservoir, which
79 can initiate additional blood-stage infections weeks to months after initial infection¹³. Clearing
80 this relapsing hypnozoite reservoir from the liver is hindered by incomplete drug efficacy¹⁴,
81 toxicity¹⁵, and adherence concerns¹⁶. In the blood stage, *P. vivax* invades a smaller subset of
82 erythrocytes¹⁷ and thus more frequently creates submicroscopic infections, especially in
83 adults¹⁸. *P. vivax* also develops transmissible gametocytes approximately one week earlier than

84 *P. falciparum*. This increases the likelihood of onward transmission before antimalarial treatment
85 occurs^{19,20}. Several experimental infection studies have additionally suggested that the minimum
86 gametocyte density required to infect susceptible mosquitoes is intrinsically lower in *P. vivax*
87 than in *P. falciparum*^{19,21–25}.

88 Taken together, the above properties are thought to make *P. vivax* more resilient to clinical
89 interventions targeting symptomatic pediatric infection, a main focus of *P. falciparum* control.
90 Vector control measures are also thought to have weaker or delayed effects on *P. vivax* due to
91 post-intervention relapse from undetected or unsuccessfully cleared hypnozoite reservoirs, and
92 higher probability to achieve onward transmission when mosquito abundance is low.
93 Furthermore, long-lasting hypnozoite reservoirs and more transmissible asymptomatic blood-
94 stage infections may make *P. vivax* more effective at long-distance dispersal and outcrossing
95 with unrelated strains. This may also include greater potential for allochthonous transmission
96 where malaria was previously absent or cleared^{26–28}.

97
98 The epidemiological effects of these biological differences between *P. falciparum* and *P. vivax*
99 have been difficult to quantify because synchronized comparative study designs that avoid
100 confounding by methodological and spatiotemporal factors are challenging to establish²⁹. Study
101 systems representing true species sympatry are also rare, as *P. falciparum* and *P. vivax* often
102 occupy distinct, only partially overlapping socio-geographic partitions within areas more broadly
103 considered co-endemic^{2,3}.

104 This study uniquely couples a spatiotemporally matched genomic sampling scheme with
105 epidemiological analysis of disaggregated (patient-level) malaria case records to discern co-
106 endemic *P. falciparum* and *P. vivax* transmission dynamics. We focus on Guyana, where both
107 species contribute substantially to the national case count (32.3% *P. falciparum*, 67.4% *P. vivax*,
108 and <1% *P. malariae* in 2019) and where true sympatry is geographically widespread. Malaria in

109 Guyana also involves a diverse mix of ethnicities (e.g., strong representation from
110 Afroguyanese, East Indian, and Amerindian ethnicities) and dynamic population mobility
111 patterns relating to the mining field. Next to important distinctions relating to geographic and
112 host demographic variables, we demonstrate clear species contrasts in strain ancestry,
113 persistence, dispersal, and infection complexity within this multifaceted transmission context.
114 We discuss possible biological drivers behind divergent species epidemiologies and identify
115 various implications for intervention.

116

117 **Results**

118 ***General spatiotemporal species prevalence***

119 We first conducted a descriptive summary of country-wide passive case detection records made
120 available by the Guyana Ministry of Health (GMOH) for 2006 to 2019. Rolling monthly counts
121 demonstrate well-balanced case burden between species from 2006 to 2010 followed by higher
122 *P. falciparum* incidence from 2010 to 2013 ([Fig. 1a](#)). *P. vivax* cases began to exceed those of *P.*
123 *falciparum* in mid-2013 and remained overrepresented until 2019. Individual-level case
124 metadata have been curated by the GMOH for 2019. We therefore focus on 2019 for most
125 subsequent epidemiological analyses. 2019 records include 17,710 single-species cases
126 (67.4% *P. vivax*, 32.3% *P. falciparum*, and 0.2% *P. malariae*) and 1,001 mixed-species cases
127 containing both *P. vivax* and *P. falciparum* ([Supplementary Table 1](#)). Both species show
128 transmission throughout the year and elevated incidence between April and August
129 ([Supplementary Fig. 1](#)).

130 ***Species intricacies of a wide co-endemic distribution***

131 2019 case records show the extent of *P. falciparum* – *P. vivax* geographic and demographic co-
132 endemicity in Guyana ([Fig. 1b-d](#)). Regions I, VII, and VIII account for 94.6% of *P. falciparum*
133 cases and 89.3% of *P. vivax* cases, and regional species proportions remain stable across East

134 Indian, Amerindian and Mixed/Other ethnicity groups. While *P. vivax* consistently predominates
135 in these groups, case majority flips to *P. falciparum* in the Afroguyanese (Chi-squared tests, χ^2
136 = 36.13 (I), 269.63 (VII), 125.51 (VIII), $p < 0.001$ (all regions), [Fig. 1b](#)). We further classified
137 infection localities into 27 epidemiological zones (average 3,631 km² each) defined using river-
138 road transport networks and mobility friction maps ([Fig. 1c](#), [Supplementary Fig. 2](#)). Again,
139 species sympatry is consistently maintained in all zones within Regions I, VII, and VIII. The
140 relative proportion of *P. vivax* cases is generally higher outside of this main malaria range,
141 especially to the south in Region IX (e.g., Upper Rupununi and Greater Lethem). Patients aged
142 15 -54 clearly predominate in both species but are more common in *P. falciparum* (84.5%) than
143 in *P. vivax* (79.2% – Chi-squared test, $\chi^2 = 82.89$, $p < 0.001$, [Fig. 1d](#)). The proportion of cases
144 representing *P. falciparum* also increases markedly with age in male patients (Kruskal-Wallis
145 test, $H = 23.64$, $p < 0.001$ – see post-hoc significance in [Fig. 1e](#)). Working-age (≥ 15 years) to
146 child (< 15 years) case ratios are less markedly elevated in Amerindians than in non-Amerindian
147 ethnicities (3.8 to 1 vs. 13.5 to 1, respectively, for *P. falciparum* (Chi-squared test, $\chi^2 = 273.84$,
148 $p < 0.001$) and 2.6 to 1 vs. 7.4 to 1, respectively, for *P. vivax* (Chi-squared test, $\chi^2 = 515.98$, $p <$
149 0.001), [Supplementary Fig. 4](#)). Elevated case bias towards non-Amerindian working-age males
150 is consistent with gold mining driving malaria burden in Guyana³⁰, especially in non-resident
151 (e.g., ‘coast lander’³¹) mining groups. Higher working-age to child case ratio for *P. falciparum* vs.
152 *P. vivax* may also suggest that transmission from mining to non-mining communities, and
153 sustained transmission in non-mining communities, is less common in *P. falciparum* than in *P.*
154 *vivax*.

155 **Deep genomic profiling of each species across 2020 and 2021**

156 To search for epidemiological features that are not observable from traditional symptomatic
157 case analysis, we sequenced 708 *P. falciparum* and 762 *P. vivax* genomes from patient blood
158 spots collected passively by the GMOH. Collection followed informed consent using a study

159 protocol approved by ethical committees of Harvard University and the government of Guyana.
160 Sequencing was successful for 666 *P. falciparum* and 705 *P. vivax* genomes ([Supplementary](#)
161 [Table 2](#)) continuously spanning January 2020 to June 2021 ([Fig. 2](#)). Of these 1,371 samples,
162 1,216 (89%) are coupled with patient travel history records used to infer geographic infection
163 source (representing Regions I, VII, and VIII in 1,156 (95.1%) samples). We additionally
164 sequenced 7 *P. falciparum* and 16 *P. vivax* samples from 2019 representing infections from
165 Venezuela and analyzed two publicly available Venezuelan *P. falciparum* genomes from
166 2015/16 (European Nucleotide Archive (<https://www.ebi.ac.uk>) accessions ERR1818176 and
167 ERR2496572).

168 ***Discrepant genomic diversity and relatedness between species***

169 Genomic analyses focused on 46,067 and 266,141 sites with segregating single-nucleotide
170 polymorphisms (SNPs) identified in the *P. falciparum* and *P. vivax* sample sets (respectively)
171 following quality filtration steps (see Methods). This difference in the number of segregating
172 sites and in average pairwise nucleotide diversity observed within each sample set ($1.99 \cdot 10^{-4}$
173 differences per bp in *P. falciparum* and $2.91 \cdot 10^{-4}$ differences per bp in *P. vivax*, [Supplementary](#)
174 [Fig. 5](#)) align with previous evidence that genetic diversity is higher in *P. vivax* at the global
175 scale³².

176 To further characterize diversity within each sample set, we applied a hidden state model³³ to
177 estimate parasite relatedness due to recent common ancestry (identity-by-descent; IBD) for all
178 monoclonal sample pairs (we excluded 250 samples identified as multi-strain infections using a
179 Bayesian framework³⁴). The relatedness distributions ([Fig. 3a](#)) clearly differ between the two
180 species (Kolmogorov-Smirnov test, $D = 0.99$, $p < 0.001$). Pairwise relatedness values in *P. vivax*
181 exhibit a mean of 0.048, with very little standard deviation ($sd = 0.031$) and minimal skew or
182 outlier occurrence. These results are indicative of a diverse, frequently outcrossing population
183 without substantial sub-clustering into groups of highly related individuals. In contrast, most

184 pairwise comparisons in *P. falciparum* exhibit greater than half-sibling-level relatedness (mean =
185 0.310 ± 0.124 sd). The broader, right-tailed relatedness distribution also includes a peak near 1
186 representing the presence of identical clones as well as values between 0.5 and 0.75
187 representing the presence of various inbred sibling-level relationships. A network analysis
188 identified 79 clonal groups (>0.90 IBD) among *P. falciparum* samples, represented by 2 to 39
189 members each ([Supplementary Fig. 6](#)). Clonal group membership detection was often
190 spatiotemporally aggregated (e.g., $>50\%$ of group members detected within 4 months per
191 epidemiological zone, [Supplementary Fig. 7](#)), consistent with outbreak-like patterns of
192 prevalence³⁵. The largest clonal groups spread across multiple geographic areas
193 ([Supplementary Fig. 8a](#)), and most appear highly interrelated (e.g., 50 groups collapse into a
194 single network when re-clustering samples at >0.60 IBD, [Supplementary Fig. 6](#)). Four groups
195 noted with asterisks in [Supplementary Fig. 6](#) and mapped in [Supplementary Fig. 8b](#) appear
196 slightly divergent (1.7 to 3.3 sd below average between-group IBD). Other clonal patterns
197 mapped in [Supplementary Fig. 8b](#) include the clustering of groups #7, #9, and #10 around Port
198 Kaituma and Mabaruma (Region I), groups #18, #24, and #49 along the Mazaruni and Puruni
199 Rivers (Region VII), and groups #27, #32, and #52 around Mahdia and the lower Potaro River
200 (Region 8). Two divergent clonal pairs (#20 and #65) also have partial membership in
201 Venezuela (star symbols in [Supplementary Fig. 8b](#)) and likely represent transmission of
202 imported parasite lineages ([Supplementary Text 1](#), [Supplementary Fig. 9](#)). Group #20 also
203 represents a case of longer-term clonal persistence from 2015 to 2020.

204 Clonal network analysis results for *P. vivax* are very different. We observe only 29 clonal
205 groups, of which 23 contain 2 members each and 6 contain 3 members each. Post-hoc review
206 of patient-specific case codes (blinded to non-GMOH authors) also clarifies that 11 of 23 clonal
207 pairs represent repeated sampling from the same patient (median time between 1st and 2nd
208 visit = 109 days (minimum = 40 days, maximum = 229 days). These likely represent relapses

209 registered as new infections prior to genetic analysis. No close relatedness occurs among any
210 clonal groups (the same number of groups created via clustering at >0.90 IBD remains when re-
211 clustering at >0.30 IBD) or between Guyanese and Venezuelan sample sets ([Supplementary](#)
212 [Fig. 6](#), [Supplementary Text 1](#), [Supplementary Fig. 9](#)). Furthermore, clonal persistence in *P.*
213 *vivax* (average = 79 days, maximum = 243 days) appears more temporally limited (Wilcoxon
214 test, $W = 55078$, $p = 0.003$) than in *P. falciparum* (median = 113.5 days, maximum = 500 days,
215 excluding imported lineages (groups #20 and #65), [Supplementary Fig. 10](#)).

216

217 ***Regional isolation-by-distance in P. falciparum vs. micrographic structure in P. vivax***

218 We next evaluated whether parasite genetic relatedness declines with spatial distance (Fig. 3b).
219 The presence of 'isolation-by-distance' is a common indicator of population structure due to
220 spatially limited dispersal, understanding of which is key to the success of control objectives
221 such as limiting the spread of drug resistance^{36,37}. We applied sliding windows of spatial
222 distance, quantifying the fraction of pairwise comparisons in each 30 km window that showed
223 >0.50 IBD. Results for *P. falciparum* demonstrate a linear decrease in the frequency of >0.50
224 IBD as spatial distance increases between sample pairs (Pearson's $r = 0.89$, $p < 0.001$).
225 Exceptions occur at window starts near 100 km and 200 km where the frequency of close
226 relatives briefly rebounds to levels observed at shorter distance classes. These upticks may
227 reflect accumulation of relatedness between common travel hubs or mining foci and
228 discontinuous transmission risk during interregional host movement.

229

230 In *P. vivax*, sample pairs with >0.50 IBD were very rare ($n = 87$) but also clearly
231 overrepresented in the first spatial distance class (0-30 km, [Fig. 3](#)). A continued decline in >0.50
232 IBD frequency with spatial distance was however not apparent. To help assess whether the
233 spatial distance across which negative correlation between relatedness and spatial distance

234 persists differs between species, we quantified 99th percentile (p99) IBD, an alternative
235 definition of close ancestry that normalizes statistical power in comparative Mantel tests
236 ([Supplementary Fig. 11](#), top). Correlogram results for *P. falciparum* indicated significant
237 correlation between genetic distance (1 - p99 IBD frequency) and spatial distance for 0-30 km
238 (Mantel $r = 0.49$, $p = 0.001$) as well as for 30-60 km distance classes (Mantel $r = 0.19$, $p =$
239 0.017). In *P. vivax*, correlation between 1 - p99 IBD frequency and spatial distance loses
240 statistical significance at 30-60 km (Mantel $r = 0.12$, $p = 0.089$). Shorter isolation-by-distance
241 signal relative to *P. falciparum* also occurred when using the absolute, >0.50 IBD metric to
242 define close ancestry ([Supplementary Fig. 11](#), bottom).

243 ***Genetic vs. non-genetic markers accord better on P. falciparum than on P. vivax*** 244 ***dispersal***

245 We further examined how parasite pairs exhibiting >0.50 IBD were distributed among
246 epidemiological zones ([Fig. 4](#)) and whether this parasite genetic structure correlated to patient
247 travel patterns inferred by comparing sites of patient diagnosis and prior stay (2 weeks) in the
248 epidemiological database from 2019. Examining the extent to which parasite propagation across
249 specific geographic or administrative units can be tracked and predicted using genetic or
250 traditional case metrics is important in helping determine potential to focus and tailor
251 intervention activities and surveillance data types.

252 Corollary to the clear elevation in >0.50 IBD frequency at 0-30 km ([Fig. 3](#)) and significant
253 isolation-by-distance at 0-30 km ([Supplementary Fig. 11](#)) in both *P. falciparum* and *P. vivax*,
254 both also generally showed highest frequencies of elevated relatedness within (i.e., not
255 between) epidemiological zones ([Fig. 4](#)). This observation from the genomic data matches the
256 observation from the epidemiological database that the majority of symptomatic malaria cases
257 involve non-mobile, 'local' infections (black pie slices, [Supplementary Fig. 12](#)), i.e., patients
258 reporting absence of travel 14 days prior to diagnosis. The epidemiological data also suggest

259 that the proportion of local to nonlocal infections (i.e, cases in which patients reported having
260 stayed in a distinct epidemiological zone 14 days prior to diagnosis) is higher for *P. vivax* than
261 for *P. falciparum* in 16 of 23 analyzed epidemiological zones ([Supplementary Fig. 13](#)). These 16
262 zones include non-endemic coastal areas such as Greater Georgetown, where 178 of 1,611
263 (11.0%) *P. vivax* patients (vs. 45 of 867 (5.2%) *P. falciparum* patients) reported absence of prior
264 travel (Chi-squared test, $\chi^2 = 22.915$, $p < 0.001$). Elevated pairwise nucleotide diversity
265 (+20.7% π) in *P. vivax* samples attributed to Greater Georgetown (Welch's t test, $t = 4.71$, $p <$
266 0.001 , [Supplementary Fig. 5](#)) further supports the hypothesis that relapses representing various
267 different geographic infection sources are diagnosed in this capital district.

268

269 To statistically compare inference of parasite movement based on genetic vs. epidemiological
270 data types, we correlated the relative frequency of parasite >0.50 IBD and patient travel events
271 ('case flow') among all pairs of endemic epidemiological zones for which patient movement was
272 detected in the epidemiological database (i.e., all arrowed segments in [Supplementary Fig. 12](#)).
273 In the case of *P. falciparum*, relative frequencies of >0.50 IBD and case flow were moderately
274 correlated (Pearson's $r = 0.44$, $p = 0.029$) between endemic zones ([Fig. 5](#)), with most
275 conspicuous congruence in the context of reduced connectivity between Region I and Regions
276 VII and VIII (e.g., see short spokes of elevated >0.50 IBD frequency and intensified case flow
277 around Kaituma and Barima in Region I, yet limited connectivity farther South in [Fig. 4](#) and
278 [Supplementary Fig. 12](#)). Only 0.8% of nonlocal infections sampled in Regions VII and VIII (grey
279 pie slices, [Supplementary Fig. 12](#)) represented infection sites from Region I. Case flow to
280 Greater Georgetown was also weaker for infections attributed to Region I (36.4%) than for
281 infections attributed to Region VII (43.4% – Chi-squared test, $\chi^2 = 48.22$, $p < 0.001$) or to
282 Region VIII (74.1% – Chi-squared test, $\chi^2 = 874.35$, $p < 0.001$). These results may in part
283 reflect the absence of efficient travel routes from Region I to Georgetown (East) and to Regions
284 farther South. Rivers key to travel in Region I (e.g., the Barima and Barama) lead into a

285 Northwest delta while those key to travel in Regions VII and VIII (e.g., the Cuyuni and Mazaruni)
286 flow East into the Essequibo near Georgetown. A handful of semi-developed roads also parallel
287 and connect areas of the Cuyuni, Mazaruni, and Essequibo in Regions VII and VIII.

288 For *P. vivax*, the frequency of >0.50 IBD also correlated significantly with case flow between
289 endemic zones (Pearson's $r = 0.51$, $p < 0.001$, [Fig. 5](#)). Unlike in *P. falciparum*, however,
290 significance is lost when broadening the classification of elevated relatedness to p99 IBD
291 ([Supplementary Fig. 14](#)). This observation helps clarify that the significant relationships detected
292 when regressing >0.50 IBD frequency on spatial distance ([Fig. 3](#)) and case flow ([Fig. 5](#)) do not
293 mean that the *P. vivax* population is predictably structured as a whole. Results are instead
294 consistent with a dispersive, frequently outcrossing *P. vivax* population in which pairwise
295 relatedness is swiftly erased and local genotype associations are rarely established. In this
296 scenario, the ephemeral presence of intact clones or sibling-level relatives creates micrographic
297 spatiotemporal autocorrelations that are not representative of broader population dynamics.

298 ***Higher outcrossing potential in P. vivax – do relapse and risk carryover play a role?***

299 We further assessed indications from relatedness analyses that outcrossing rate is elevated in
300 *P. vivax* by examining polyclonality rate (i.e., the fraction of samples containing multiple distinct
301 strains) and its variation with respect to geographic and demographic variables. Polyclonality
302 rate is closely related to outcrossing rate because parasite sexual recombination in the
303 mosquito after blood meal only results in outcrossing if multiple distinct strains are ingested
304 simultaneously from the human host.

305 We observed a polyclonality rate of 24.0% in *P. vivax* vs. 11.4% in *P. falciparum* (Chi-squared
306 test, $\chi^2 = 36.72$, $p < 0.001$, [Fig. 6a](#)). Elevated *P. vivax* outcrossing rate implied by this 2.1x
307 polyclonality rate differential helps explain the aforementioned paucity in clonal relationships
308 ([Fig. 3](#)) and their limited persistence over time ([Supplementary Fig. 10](#)). It is also consistent with

309 the observation that linkage disequilibrium between SNPs declines across physical genetic
310 distance more readily in *P. vivax* than in *P. falciparum* ([Supplementary Fig. 15](#)).

311 Polyclonality rate is considered a positive correlate of *P. falciparum* transmission intensity in the
312 absence of high rates of case importation³⁸. We assessed this possible relationship in *P.*
313 *falciparum* and *P. vivax* (in which polyclonality may additionally occur via hypnozoite-based
314 relapse) by plotting polyclonality rates per epidemiological zone against corresponding
315 incidence estimates ([Fig. 6b](#), see Methods). Interestingly, *P. vivax* polyclonality rates remain
316 consistently inflated, regardless of incidence estimate. Polyclonality rate and incidence
317 estimates also trend in opposite directions for *P. falciparum* vs. *P. vivax*, though neither
318 achieves statistical significance. Polyclonality rate was highest in *P. vivax* infections from the
319 Lower Essequibo zone, a key area of travel convergence from the hinterlands of Region VII but
320 one in which malaria risk is not considered high. These results may indicate that *P. vivax*
321 samples from areas of lower endemicity are more likely to represent imported cases (possibly in
322 the form of relapse) that involve multiple accumulated strains.

323 To further understand polyclonality rate relationships to transmission risk, we compared
324 polyclonality rates in ≥ 15 year-old male and females within the three neighborhood councils
325 (NDCs) containing ≥ 20 genomic samples for each of these groups ([Fig. 6c](#)). Males represented
326 the majority of epidemiological case records in the three NDCs, suggesting that transmission
327 risk is generally higher in male-associated occupations. Polyclonality rate in *P. falciparum* thus
328 followed expectations in that observed values appeared consistently higher in males than in
329 females. Polyclonality rates in *P. vivax* were generally more variable (see confidence intervals,
330 especially in females ([Fig. 6c](#))), and were higher in females than in males in NDC VII-2, an area
331 that contains Mahdia and various popular mining sites (e.g., the Mazaruni River Quarry and the
332 Karouni Project). Interestingly, this trend was driven by polyclonality rate enrichment in females
333 among patients reporting Venezuelan nationality (Chi-squared test, $\chi^2 = 4.33$, $p = 0.037$,

334 [Supplementary Fig. 16](#)), possibly because infection risk is enhanced in female-biased
335 occupations that accompany the active mining sector (e.g., in rest/supply areas where frequent
336 contact among gametocyte-carrying male miners, mosquitoes, and female non-miners occurs).
337 Enhanced *P. vivax* transmissibility, e.g., due to presymptomatic gametocytemia, may heighten
338 this risk.

339 **Discussion**

340 In this study we coupled comparative malaria parasite population genomics with passive case
341 record metadata analyses to compare co-endemic *P. falciparum* and *P. vivax* epidemiology in
342 Guyana. We observed several key genomic epidemiological contrasts that indicate the need to
343 consider species-specific approaches to malaria intervention.

344 Most notably, we observed dramatically different patterns of genomic relatedness between the
345 two species. The *P. falciparum* sample set exhibited a relatively broad pairwise IBD distribution
346 centered near values expected for half-sibling-level relatedness, whereas in *P. vivax* this
347 distribution was less variable and clearly shifted towards zero (6.4x lower average IBD). Clonal
348 pairwise relationships (>0.90 IBD) were detected >50x more often in *P. falciparum* and most
349 clonal *P. falciparum* groups exceeded 3 samples in membership size (max. 38). Many of these
350 groups also displayed spatiotemporally aggregated, outbreak-like patterns of detection. In *P.*
351 *vivax*, clonal groups had no more than 2-3 members and appeared to persist for shorter periods
352 of time; many clonal *P. falciparum* relationships were detected between samples separated by
353 >12 months whereas for *P. vivax* the maximum time between clone detection was 243 days.

354 This strong contrast in relatedness structure may derive mechanistically from polyclonality rate
355 differences between the species. Polyclonality rate is a key determinant of the extent to which
356 clones and near-relatives can persist in transmission cycles because polyclonality is a
357 prerequisite to sexual recombination between distinct strains (outcrossing) in the mosquito

358 stage. In this study, *P. vivax* polyclonality was not only 2.1x higher than in *P. falciparum* at the
359 population level, but also remained consistently inflated when accounting for estimated
360 incidence in subgeographic comparisons. This result suggests that elevated polyclonality rates
361 in *P. vivax* are not a product of higher infection incidence alone. *P. vivax* relapse from the
362 dormant hypnozoite liver stage likely represents an additional source of polyclonality because
363 relapse can overlap with current infection and can involve the successive activation of divergent
364 strains³⁹.

365 Importantly, though humans are the common agent of dispersal throughout Guyana for both
366 parasite species, we observed highly contrasting patterns of spatial genetic structure. The
367 frequency of close *P. falciparum* relatives (>0.50 IBD) decayed with geographic distance, and
368 selected clonal genotypes could be linked to specific geographic subdivisions in Guyana. In *P.*
369 *vivax*, significant correlation of relatedness with spatial distance did not occur among sample
370 pairs separated by >30 km, and meaningful regional population structure could not be resolved.
371 Limited macrogeographic structure in *P. vivax* may occur largely because the dormant hypnozoite
372 liver stage unique to this species facilitates long-distance dispersal via relapse in mobile hosts.
373 Various study results point to the influence of relapse on *P. vivax* dispersal in the study region.
374 At health centers in Greater Georgetown, for example, an absence of travel 14 days prior to
375 diagnosis was reported more than twice as frequently by *P. vivax* patients (178 of 1,611
376 (11.0%)) than by *P. falciparum* patients (45 of 867 (5.2%)). Nucleotide diversity was also
377 significantly elevated in *P. vivax* samples representing such non-traveler cases. Given that
378 Greater Georgetown is considered free of malaria transmission, many non-traveler *P. vivax*
379 cases may represent reactivation of dormant parasite diversity that has accumulated in hosts
380 over longer periods of time³⁹. We also observed the recurrence of *P. vivax* clones in 11 patients
381 for which blood spots were sequenced from separate malaria visits. These same-patient sample
382 pairs represented symptomatic malaria episodes separated by a median of 109 days and the

383 prescription of a 3-day Chloroquine + 14-day primaquine treatment course. They may thus not
384 only represent direct evidence of relapse but also point to efficacy and adherence challenges
385 relating to hypnozoicidal drugs.

386

387 Together, these observations suggest that differences in underlying parasite biology are
388 contributing to divergent species responses to intervention, including flips from *P. falciparum* to
389 *P. vivax* case majority observed over the last 15 years in regions nearing elimination goals (e.g.,
390 Guyana, Solomon islands, Myanmar, Cambodia, Lao PDR¹).

391 In the case of *P. falciparum* in Guyana, malaria control strategy may benefit from further
392 advancing decentralized case management and differentiating resource allocation based on
393 real-time spatiotemporal surveillance. Similar to regions in Southeast Asia where these
394 approaches have recently reduced *P. falciparum* cases to historic lows⁴⁰, our study indicated a
395 *P. falciparum* metapopulation maintained by periodic expansions from high-risk transmission
396 areas (mines in remote riparian forest) where infrastructure is limited and occupational
397 incentives conflict with self-care. In these settings, treatment-seeking is more likely to be
398 delayed (increasing the risk of transmission prior to treatment) and access to regional treatment
399 centers may involve long-distance travel through endemic terrain. It therefore may be beneficial
400 to further decentralize medical capacity from regional treatment centers to localities with strong
401 outbreak signals (e.g., Puruni Landing) or to strategic points along travel routes that may
402 facilitate parasite dispersal (e.g., along the Mazaruni River, a possible conduit for clonal *P.*
403 *falciparum* dispersal based on this study). Self-administered diagnostic and treatment
404 approaches (e.g., Malakit⁴¹) might additionally help cover remote areas, with monitoring to
405 evaluate the extent to which incorrect self-treatment may negatively impact user health or
406 contribute to resistance emergence.

407 In the case of *P. vivax* control, our study suggests that similar strategies of decentralized and
408 focally intensified intervention will be less efficacious. We do not observe tractable
409 metapopulation structure that would help prioritize intervention foci, and various results point to
410 the risk of latent dispersal processes undermining geographically differentiated intervention.
411 Decentralizing treatment resources, especially the integration of unsupervised treatment kits,
412 also appear less tractable due to the greater complexity of safe and effective 'radical' *P. vivax*
413 cure (treatment targeting both bloodstage and hypnozoite parasites). Hypnozoite clearance
414 generally involves two-week treatment with 8-aminoquinolone drugs and requires prior glucose-
415 6-phosphate dehydrogenase (G6PD) deficiency assessment of haemolysis risk¹⁵. This also
416 makes conventional mass drug administration approaches targeting latent *P. vivax* reservoirs
417 difficult to realize in settings without exceptionally low rates of G6PD deficiency⁴² and
418 exceptionally consistent treatment compliance⁴³. It is therefore necessary to advance work on
419 alternative implementation strategies (e.g., CUREMA⁴⁴ approaches to radical cure in medically
420 underserved populations of the Guiana Shield) and towards the discovery of new hypnozoicidal
421 drugs.

422 In the interim, fortifying preventive vector control and risk awareness programs is also important.
423 A recent study suggests that increased risk perception is associated with increased preventive
424 behavior against vector borne disease in Guyana, although effect size is small (4-5%)⁴⁵. Effect
425 size might be increased if educational programs more strongly convey risk of onward malaria
426 transmission as opposed to risk solely towards personal health. Such altruistic risk perception
427 may be relevant to the more rapid, pre-symptomatic spread of *P. vivax* malaria into local
428 vectors, including upon miner return to non-mining home environments.

429 This study had several limitations. Importantly, the near-relative detection approach we used to
430 describe parasite population structure focuses on outlier IBD relationships and therefore
431 underuses available sequence content. We also did not infer IBD relationships involving

432 polyclonal infections, which constituted 17.9% of our genomic sample set. Furthermore,
433 genomic sample collection relied on a sentinel method which may bias against parasite diversity
434 found in remote, disconnected transmission cycles (e.g., Amerindian settlements). It was also
435 challenging to address the transitory nature of human settlement in the hinterlands of Guyana,
436 where conventional population sizes are not recorded or do not apply. This primarily
437 complicated the estimation of zonal incidence and its relationship to polyclonality rates. High
438 host mobility in undercharted hinterland areas also added uncertainty to geographic infection
439 source estimates.

440 Despite these limitations, this study clearly exposes the discrepant profiles of co-endemic *P.*
441 *falciparum* and *P. vivax* malaria in a low transmission setting, and emphasizes the need for
442 distinct intervention and surveillance approaches in order to succeed in eliminating both
443 species. The current disproportionate investment in drugs, vaccines, and monoclonal antibodies
444 for *P. falciparum* increases the likelihood that *P. vivax* will persist in many co-endemic regions
445 after *P. falciparum* is eliminated, forestalling the ultimate goal of eliminating malaria from all
446 regions and demographics.

447 **Methods**

448 ***Epidemiological database and definitions/categorizations***

449 The epidemiological database analyzed in this study comprised all malaria episodes detected in
450 Guyana via passive surveillance (estimated to represent approximately 80% of cases¹) and
451 reported to the National Malaria Program between 2007 and 2019. Malaria episodes were
452 defined using both medical diagnoses and parasitological tests (blood microscopy, and less
453 commonly, rapid diagnostic tests). Patient records were curated by the Vector Control Services
454 (VCS) division of the GMOH and anonymized records of patient age, gender, nationality, and
455 self-reported ethnicity (categorized as “Afroguyanese”, “Amerindian”, “East Indian”, “Chinese”,
456 “Portuguese”, “European”, “Mixed”, or “Other”) were provided to the Harvard T.H. Chan School

457 of Public Health (HSPH) following approval by the Harvard University Area Human Research
458 Protection Program (protocol IRB18-1638) and by ethical committees of the GMOH. Infection
459 localities were inferred based on voluntary responses about “*Where [the] patient stayed 2*
460 *weeks ago*” (see survey form in [Supplementary Fig. 17](#)). Each travel history response was
461 classified to one of 460 country-wide localities with known latitude/longitude coordinates.

462
463 To define epidemiological zones, we mapped malaria survey sites used by the GMOH
464 (<https://gazetteer.gls.gov.gy/gazetteer/#7/3.650/-57.129>) onto a custom shape file containing
465 Guyana’s primary river and road coordinates and onto a motorized transport resistance raster
466 obtained from <https://malariaatlas.org/> ([Supplementary Fig. 2](#)). Sites were clustered based on
467 river/road connectivity in the R package RIVERDIST⁴⁶ v0.16.3, travel conductance using the R
468 package GDISTANCE⁴⁷ v1.6.4, and manual assessment of river/road and resistance layers in
469 QGIS⁴⁸ v2.18.4. Transmission intensity was estimated for each epidemiological zone using
470 population size estimates from the LandScan Project⁴⁹. The LandScan approach uses
471 dasymetric modeling to disaggregate census counts based on remotely sensed images⁴⁹. We
472 used Landscan Global 2019 data to estimate average population density within 10 arcmin (ca.
473 20 km) of the centroid representing all localities contributing malaria cases within an
474 epidemiological zone. We then divided the zonal case count by its LandScan population density
475 estimate.

476 ***Clinical sample material, sequencing, and variant calling***

477 Following informed consent to analyze parasite genetic polymorphism using patient blood,
478 samples were collected from microscopy or RDT-positive patients by spotting approximately 50-
479 200 µl whole blood onto Whatman FTA filter paper cards. Collection was carried out by VCS
480 between January 2020 and June 2021 at medical facilities in Bartica, Georgetown, Mahdia,
481 Lethem, and Port Kaituma, Guyana. Samples were stored at room temperature using individual

482 desiccant packets before shipment to HSPH. The same anonymized patient metadata variables
483 as described in the previous section ([Supplementary Fig. 17](#)) were also provided to HSPH. An
484 additional 23 dried blood spot samples were collected in Venezuela at the Institute of Tropical
485 Medicine, Central University of Venezuela (Caracas, bioethics permit CEC-IMT 12/2013) and
486 Biomedical Research and Therapeutic Vaccines Institute (Ciudad Bolívar, bioethics permit
487 CHURPCBBS-008-2019) in 2019. Metadata for these samples (collection date and reported
488 place of stay (municipality) two weeks prior to diagnosis) was likewise de-identified prior to
489 HSPH access ([Supplementary Table 2](#)).

490 We extracted total genomic DNA from dried blood spot samples (approximately 20-35 mm²
491 spotted area punched per sample) using KingFisher Ready DNA Ultra 2.0 Prefilled Plates on
492 the Kingfisher Flex instrument (ThermoFisher Scientific). We subsequently applied whole-
493 genome amplification to DNA extracts using sets of ten *P. falciparum*⁵⁰ and/or *P. vivax*-selective
494 oligos⁴⁴ (set selection based on previous microscopy or RDT-based species assignment) and
495 used AMPure XP magnetic beads (Beckman Coulter) to exchange post-reaction sample buffer
496 to 10 mM Tris-HCl + 0.1 mM EDTA. Final library construction using the NEBNext Ultra II FS
497 DNA Library Prep Kit (NEB #E6177) and 2 x 150 bp sequencing on the Illumina HiSeqX
498 platform (150-bp paired-end reads) was completed at the Broad Institute. We aligned reads to
499 the *P. falciparum* 3D7 and *P. vivax* PvP01 reference genome assemblies using BWA-MEM⁵²
500 and called SNPs and INDELS using GATK⁵³ v3.5-0-g36282e4 'HaplotypeCaller' and
501 'GenotypeGVCFs' according to best practices defined by the Pf3k consortium
502 (http://www.malariagen.net/data_package/pf3k-5/). The mapping and joint variant call process
503 also included sample accessions ERR1818176 and ERR2496572 representing malaria
504 infections from Venezuela (further geographic specifics unknown). All downstream genetic
505 analysis focused on SNP sites in core regions of the genome^{54,55} and >5 bp from any INDEL

506 call. The base SNP call set created for each species also excluded sites at which >7.5% of
507 monoclonal samples showed multi-allelic ('heterozygous') calls.

508 **Parasite genetic analyses**

509 We assessed polyclonality using THEREALMcCOIL³⁴ v2, a Bayesian Markov chain Monte Carlo
510 approach that simultaneously estimates population allele frequency for each SNP and COI for
511 each individual in the sample set. We applied the categorical method (classifying SNP calls
512 binarily as homozygous or heterozygous regardless of the signal intensity of each component
513 allele) to bi-allelic SNP sites with $\geq 10\%$ minor allele frequency and $\geq 90\%$ call success across
514 samples. We further subsampled input to limit computational costs. Subsampling using the '--
515 thin' function in VCFtools⁵⁶ v0.1.15 resulted in 337 *P. falciparum* and 350 *P. vivax* input sites.
516 We kept input parameters in default and used the lower bound (quantile = 2.5%) output value as
517 a conservative estimate of sample COI.

518

519 Analyses of genetic diversity and relatedness only included monoclonal samples. We estimated
520 nucleotide diversity from the base SNP call sets (previous section) by measuring average
521 nucleotide differences over discrete 100 kbp windows (no overlap) with VCFtools⁵⁶ v0.1.15. We
522 measured linkage decay over bi-allelic SNP sites by recoding calls to non-reference allele
523 counts (0, 1, or 2) and computing linkage (r^2) in sliding 10 kbp windows (200 bp steps) in
524 PLINK⁵⁷ v1.90b1g.

525 We estimated genetic relatedness between samples based on the concept of IBD. Unlike
526 identity by state (IBS), IBD specifically represents genetic similarity inferred to have been
527 inherited from a common ancestor based on factors affecting linkage likelihood such as
528 population allele frequency, recombination rate, and chromosomal distances between variant
529 sites. IBD generally enhances representation of recent ancestry in obligately sexual species in
530 which divergence history is influenced more strongly by recombination than by the individual

531 accumulation of point mutation events. We ran hmmlBD³³ in default settings to estimate
532 population allele frequency and infer presence or absence of IBD at all bi-allelic SNPs with $\geq 2\%$
533 minor allele frequency and $\geq 70\%$ call success across samples. We used the fraction of all
534 variant sites inferred as IBD ('fract_sites_IBD') to summarize relatedness for each sample pair.

535 We used the R package IGRAPH⁵⁸ v1.3.5 to generate connected graphs (clusters) in which
536 edges represent sample pairs with relatedness values above a specified threshold. Clusters
537 therefore represent groups of samples (nodes) in which each sample is connected by at least
538 one direct edge to another sample (but simultaneous direct connections to additional cluster
539 members are not required).

540 We also correlated relatedness values to Euclidean distances calculated from latitude and
541 longitude (WGS 84) coordinates projected onto a common xy plane (EPSG 3786). We used
542 Mantel tests to assess statistical significance between genetic and spatial distance matrices
543 using the R package VEGAN⁵⁹ v2.6-4. We applied repeated random draws of 10 samples from
544 each epidemiological zone (drawing until depletion without replacement) to build each distance
545 matrix. We also mapped the frequency of pairwise relatedness between epidemiological zones
546 using shape files from the Natural Earth public domain map dataset⁶⁰.

547 Finally, we also assessed the possibility that cases of clonal IBD detection in *P. vivax* represent
548 repeated blood spot sampling events from the same patient (e.g., a first clinical visit due to
549 primary infection and one or more later clinical visits due to relapse or recrudescence by the
550 same parasite genotype). HSPH authors sent a query list of 705 *P. vivax* samples to the GMOH
551 and the GMOH flagged each according to whether it represents a patient which is also
552 represented by another sample in the query list. The list returned by the GMOH indicated 1x
553 (i.e., non-repeat) patient representation for 589 samples, 2x patient representation for 92
554 samples (necessarily representing 46 patients) and $\geq 3x$ patient representation for 22 samples

555 (necessarily representing ≤ 7 patients). The returned list did not specify which sample sets
556 corresponded to the same patient.

557

558

559 **Main figure legends**

560 **Fig. 1 Spatiotemporal and demographic patterns of *P. falciparum* and *P. vivax* in Guyana.**

561 **a)** Weekly reported cases (points) and 30-days rolling average (line) between 2006 and 2019.

562 **b)** Percent of cases representing *P. falciparum* (% Pf) by region and ethnicity in 2019. Asterisks

563 indicate significant differences in % Pf between Afroguyanese and non-Afroguyanese cases in

564 each region (χ^2 -test). **c)** Cumulative case count in epidemiological zones with >500 total cases

565 in 2019. Zones on the y-axis are ordered by *P. vivax* case count (descending from top to

566 bottom). **d)** Case counts by gender and age in 2019. **e)** % Pf by gender and age in 2019.

567 Asterisks indicate significant differences between age groups (Dunn test).

568 **Fig. 2 Spatiotemporally matched *P. falciparum* and *P. vivax* sampling in Guyana.** Colors in

569 the map and histograms represent the neighborhood councils (NDCs) to which infections from

570 2020-21 were attributed based on patient response about location of stay 14 days prior to

571 diagnosis. NDCs within Regions I, VII, and VIII are labeled in the map.

572 **Fig. 3 Pairwise IBD and relationships to spatial distance in *P. falciparum* and *P. vivax* in**

573 **Guyana. a)** Histogram of pairwise IBD in 2020-21. The y-axis is log₁₀-scaled to help display

574 less frequent close-relative observations. Dashed lines indicate species medians. **b)**

575 Relationship of spatial distance between inferred infection sites and the frequency of >0.50 IBD

576 in 2020-21. Windowed calculation using step size = 10 km and starting at 0-30 km. Error bars

577 represent 90% confidence intervals from bootstrapping 1000x. The model $y = a * e^{-(b * x)} + c$

578 was used to fit regression lines of linear and logarithmic shape. Clonal *P. falciparum* groups
579 represented by ≥ 10 members are excluded from distance analyses.

580 **Fig. 4 Frequency of >0.50 IBD within and between epidemiological zones in *P. falciparum***
581 **and *P. vivax* in Guyana.** Nodes indicate epidemiological zones. Node and segment colors
582 indicate frequency of >0.50 IBD within and between epidemiological zones (respectively) in
583 2020-21. Node sizes are proportional to genomic sampling size. Between-zone comparisons
584 represented by ≤ 50 comparisons are excluded.

585 **Fig. 5 Relationship between patient case flow and the relative frequency of >0.50 IBD in**
586 ***P. falciparum* and *P. vivax* in Guyana.** Genetic data (y-axis) represents 2020-21 and
587 epidemiological (case flow) data (x-axis) represents 2019. Point color indicates the spatial distance
588 separating the zones being compared. Comparisons represented by ≤ 50 comparisons
589 excluded. Grey shading indicates 95% confidence intervals predicted by linear regression
590 (dashed line). Labeled points represent 1) Central Coast (CC) to Lower Cuyuni (LC), 2) Head
591 Waini (HW) to Kaituma and Barima (KB), 3) Lower Potaro (LP) to Mid Essequibo, 4) KB to
592 Waini, 5) CC to Lower Mazaruni (LM), 6) KB to North Delta (ND), 7) LC to LM, 8) Head
593 Mazaruni to LM, 9) Cristinas Border to LM, 10) LM to Mid Mazaruni and Issano Rd, 11) LM to
594 Upper Cuyuni, 12) CC to KB, 13) LM to ND, 14) East of Georgetown to LP, 15) LM to Upper
595 Rupununi (UR), 16) LP to UR, 17) Greater Lethem to LM, and 18) LM to LP.

596 **Fig. 6 Polyclonality rates and relationships to estimated incidence and patient gender in**
597 ***P. falciparum* and *P. vivax* in Guyana. a)** Complexity of infection (COI) values in 2020-21,
598 population-wide. **b)** Polyclonality rate (2020-21) vs. estimated incidence (2019) in
599 epidemiological zones represented by ≥ 20 genomic samples (Kaituma_and_Barima (1),
600 Lower_Cuyuni (2), Lower_Essequibo (3), Lower_Mazaruni (4), Lower_Potaro (5),
601 Mid_Essequibo (6), Mid_Mazaruni_and_Issano_Rd (7), Upper_Cuyuni (8), Upper_Mazaruni (9),

602 Greater_GT (10)). Error bars represent 95% confidence intervals from bootstrapping 100x. c)
603 Polyclonality rate (2020-21) vs. patient gender in neighborhood district councils (NDCs)
604 represented by ≥ 20 genomic samples. Error bars represent 90% confidence intervals from
605 bootstrapping 1000x.

606 **Acknowledgements**

607 We thank the participants who contributed blood samples to the study, as well as the
608 technicians who collected and processed the samples. This study was supported by the Bill &
609 Melinda Gates Foundation (INV-009416). Under the grant conditions of the Foundation, a
610 Creative Commons Attribution 4.0 Generic License has been assigned to the Author Accepted
611 Manuscript version that might arise from this submission. This study was also supported with
612 federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of
613 Health, Department of Health and Human Services, under Grant Number U19AI110818 to the
614 Broad Institute. Sampling in Venezuela was additionally supported by the Scottish Funding
615 Council Global Challenges Research Fund (GCRF) Small Grants Fund SFC/AN/12/2017 and
616 the GCRF Vector-borne Disease Control Network (EP/T003782/1).

617 **Data Availability Statement**

618 The sequence data generated by this study have been deposited in the NCBI Sequence Read
619 Archive under BioProject PRJNA809659.

620

621

622

623

624 **References**

- 625
- 626 1. World Health Organization. WHO malaria report 2023 (WHO, 2023).
- 627 2. Weiss, D. J. et al. Mapping the global prevalence, incidence, and mortality of *Plasmodium*
628 *falciparum*, 2000-17: a spatial and temporal modelling study. *Lancet Lond. Engl.* 394, 322–331
629 (2019).
- 630 3. Battle, K. E. et al. Mapping the global endemicity and clinical burden of *Plasmodium vivax*,
631 2000-17: a spatial and temporal modelling study. *Lancet Lond. Engl.* 394, 332–343 (2019).
- 632 4. Price, R. N., Commons, R. J., Battle, K. E., Thriemer, K. & Mendis, K. *Plasmodium vivax* in
633 the era of the shrinking *P. falciparum* map. *Trends Parasitol.* 36, 560–570 (2020).
- 634 5. Oliveira-Ferreira, J. et al. Malaria in Brazil: an overview. *Malar. J.* 9, 115 (2010).
- 635 6. Rosas-Aguirre, A. et al. Epidemiology of *Plasmodium vivax* malaria in Peru. *Am. J. Trop.*
636 *Med. Hyg.* 95, 133–144 (2016).
- 637 7. Sattabongkot, J., Tsuboi, T., Zollner, G. E., Sirichaisinthop, J. & Cui, L. *Plasmodium vivax*
638 transmission: chances for control? *Trends Parasitol.* 20, 192–198 (2004).
- 639 8. Sattabongkot, J. et al. Malaria research for tailored control and elimination strategies in the
640 Greater Mekong Subregion. *Am. J. Trop. Med. Hyg.* 107, 152–159 (2022).
- 641 9. Kenangalem, E. et al. Malaria morbidity and mortality following introduction of a universal
642 policy of artemisinin-based treatment for malaria in Papua, Indonesia: a longitudinal surveillance
643 study. *PLoS Med.* 16, e100281510 (2019).
- 644 10. Sharp, P. M., Plenderleith, L. J. & Hahn, B. H. Ape origins of human malaria. *Annu. Rev.*
645 *Microbiol.* 74, 39–63 (2020).
- 646 11. Cepeda, A. S. et al. The genome of *Plasmodium gonderi*: insights into the evolution of
647 human malaria parasites. *Genome Biol. Evol.* 16, evae027 (2024).
- 648 12. Cowman, A. F., Healer, J., Marapana, D. & Marsh, K. Malaria: biology and disease. *Cell*
649 167, 610–624 (2016).
- 650 13. Krotoski, W. A. et al. Demonstration of hypnozoites in sporozoite-transmitted *Plasmodium*
651 *vivax* infection. *Am. J. Trop. Med. Hyg.* 31, 1291–1293 (1982).
- 652 14. Llanos-Cuentas, A. et al. Tafenoquine versus primaquine to prevent relapse of *Plasmodium*
653 *vivax* malaria. *N. Engl. J. Med.* 380, 229–241 (2019).
- 654 15. Recht, J., Ashley, E. A. & White, N. J. Use of primaquine and glucose-6-phosphate
655 dehydrogenase deficiency testing: divergent policies and practices in malaria endemic
656 countries. *PLoS Negl. Trop. Dis.* 12, e0006230 (2018).
- 657 16. Bruxvoort, K., Goodman, C., Kachur, S. P. & Schellenberg, D. How patients take malaria
658 treatment: a systematic review of the literature on adherence to antimalarial drugs. *PloS One* 9,
659 e84555 (2014).

- 660 17. Craik, R. A note on the erythrocytes in malaria. *The Lancet* 195, 1110 (1920).
- 661 18. Cheng, Q., Cunningham, J. & Gatton, M. L. Systematic review of sub-microscopic *P. vivax*
662 infections: prevalence and determining factors. *PLoS Negl. Trop. Dis.* 9, e3413 (2015).
- 663 19. Boyd, M. F. & Kitchen, S. F. On the infectiousness of patients infected with *Plasmodium*
664 *vivax* and *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.* s1-17, 253–262 (1937).
- 665 20. Wernsdorfer, W. H. *Malaria: Principles and practice of malariology.* (Edinburgh ; New York,
666 1988).
- 667 21. Boyd, M. F., Stratman-Thomas, W. K. & Kitchen, S. F. On the relative susceptibility of
668 *Anopheles quadrimaculatus* to *Plasmodium vivax* and *Plasmodium falciparum*. *Am. J. Trop.*
669 *Med. Hyg.* s1-15, 485–493 (1935).
- 670 22. Boyd, M. F., Stratman-Thomas, W. K. & Muench, H. The occurrence of gametocytes of
671 *Plasmodium vivax* during the primary attack. *Am. J. Trop. Med. Hyg.* s1-16, 133–138 (1936).
- 672 23. Pukrittayakamee, S. et al. Effects of different antimalarial drugs on gametocyte carriage in
673 *P. vivax* malaria. *Am. J. Trop. Med. Hyg.* 79, 378–384 (2008).
- 674 24. Galinski, M. R., Meyer, E. V. S. & Barnwell, J. W. Chapter one - *Plasmodium vivax*: modern
675 strategies to study a persistent parasite's life cycle. In: *Advances in parasitology* (eds. Hay, S. I.,
676 Price, R. & Baird, J. K.) vol. 81 1–26 (Academic Press, 2013).
- 677 25. Timinao, L. et al. Infectivity of symptomatic malaria patients to *Anopheles farauti* colony
678 mosquitoes in Papua New Guinea. *Front. Cell. Infect. Microbiol.* 11, 771233 (2021).
- 679 26. Blackburn, D. et al. Outbreak of locally acquired mosquito-transmitted (autochthonous)
680 malaria — Florida and Texas, May–July 2023. *Morb. Mortal. Wkly. Rep.* 72, 973–978 (2023).
- 681 27. Danis, K. et al. Malaria in Greece: historical and current reflections on a re-emerging vector
682 borne disease. *Travel Med. Infect. Dis.* 11, 8–14 (2013).
- 683 28. Bahk, Y. Y. et al. Epidemiological characteristics of re-emerging *vivax* malaria in the
684 Republic of Korea (1993–2017). *Korean J. Parasitol.* 56, 531–543 (2018).
- 685 29. Lopez, L. & Koepfli, C. Systematic review of *Plasmodium falciparum* and *Plasmodium vivax*
686 polyclonal infections: impact of prevalence, study population characteristics, and laboratory
687 procedures. *PLoS One* 16, e0249382 (2021).
- 688 30. De Salazar, P. M., Cox, H., Imhoff, H., Alexandre, J. S. F. & Buckee, C. O. The association
689 between gold mining and malaria in Guyana: a statistical inference and time-series analysis.
690 *Lancet Planet. Health* 5, e731–e738 (2021).
- 691 31. Hilson, G. & Laing, T. Gold mining, indigenous land claims and conflict in Guyana's
692 hinterland. *J. Rural Stud.* 50, 172–187 (2017).
- 693 32. Neafsey, D. E. et al. The malaria parasite *Plasmodium vivax* exhibits greater genetic
694 diversity than *Plasmodium falciparum*. *Nat. Genet.* 44, 1046–1050 (2012).

- 695 33. Schaffner, D. F., Taylor, A. R., Wong W., Wirth D. F. & Neafsey D. E. hmmIBD: software to
696 infer pairwise identity by descent between haploid genotypes *Malar. J.* 17, 196 (2018).
- 697 34. Chang, H.-H. et al. THE REAL McCOIL: a method for the concurrent estimation of the
698 complexity of infection and SNP allele frequency for malaria parasites. *PLoS Comput. Biol.* 13,
699 (2017).
- 700 35. Vanhove, M. et al. Temporal and spatial dynamics of *Plasmodium falciparum* clonal
701 lineages in Guyana. Preprint at <https://doi.org/10.1101/2024.01.31.578156> (2024).
- 702 36. Hubbard, A. et al. Implementing landscape genetics in molecular epidemiology to determine
703 drivers of vector-borne disease: a malaria case study. *Mol. Ecol.* 32, 1848–1859 (2023).
- 704 37. Verity, R. et al. The impact of antimalarial resistance on the genetic structure of *Plasmodium*
705 *falciparum* in the DRC. *Nat. Commun.* 11, 2107 (2020).
- 706 38. Tessema, S. et al. Using parasite genetic and human mobility data to infer local and cross-
707 border malaria connectivity in Southern Africa. *eLife* 8, e43510 (2019).
- 708 39. Popovici, J. et al. Genomic analyses reveal the common occurrence and complexity of
709 *Plasmodium vivax* relapses in Cambodia. *mBio* 9, 10.1128/mbio.01888-17 (2018).
- 710 40. Manzoni, G. et al. Progress towards malaria elimination in the Greater Mekong Subregion:
711 perspectives from the World Health Organization. *Malar. J.* 23, 64 (2024).
- 712 41. Douine, M. et al. Malakit: an innovative pilot project to self-diagnose and self-treat malaria
713 among illegal gold miners in the Guiana Shield. *Malar. J.* 17, 158 (2018).
- 714 42. Thaeler, A. D., Arnold, J. & Alving, A. S. A clinical study of primaquine (S. N. 13,272) in the
715 treatment of malaria among the Miskito Indians of Nicaragua. *Am. J. Trop. Med. Hyg.* 2, 989–
716 999 (1953).
- 717 43. Kondrashin, A. et al. Mass primaquine treatment to eliminate vivax malaria: lessons from the
718 past. *Malar. J.* 13, 51 (2014).
- 719 44. Sanna, A. et al. CUREMA project: a further step towards malaria elimination among hard-to-
720 reach and mobile populations. Preprint at <https://doi.org/10.21203/rs.3.rs-4095394/v1> (2024).
- 721 45. Lopes-Rafegas, I., Cox, H., Mora, T. & Sicuri, E. The contribution of risk perception and
722 social norms to reported preventive behaviour against selected vector-borne diseases in
723 Guyana. *Sci. Rep.* 13, 16866 (2023).
- 724 46. Tyers, M. riverdist: river network distance computation and applications. R Package version
725 0.16.3 (2024).
- 726 47. van Etten, J., de Sousa, K., & Marx, A. gdistance: distances and routes on geographical
727 grids. R Package version 1.6.4 (2023).
- 728 48. QGIS Development Team. Open Source Geospatial Foundation. Software version 2.18.4
729 (2017).

730 49. Rose, A. et al. LandScan Global 2019. Oak Ridge National Laboratory, Oak Ridge, TN
731 (2020).

732 50. Oyola, S. O. et al. Whole genome sequencing of *Plasmodium falciparum* from dried blood
733 spots using selective whole genome amplification. *Malar. J.* 15, 597 (2016).

734 51. Cowell, A. N. et al. Selective whole-genome amplification Is a robust method that enables
735 scalable whole-genome sequencing of *Plasmodium vivax* from unprocessed clinical samples.
736 *mBio* 8, (2017).

737 52. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform.
738 *Bioinformatics* 25, 1754–1760 (2009).

739 53. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing
740 next-generation DNA sequencing data. *Genome Res.* 20, 1297–1303 (2010).

741 54. Miles, A. et al. Indels, structural variation, and recombination drive genomic diversity in
742 *Plasmodium falciparum*. *Genome Res.* 26, 1288–1299 (2016).

743 55. de Oliveira, T. C. et al. Population genomics reveals the expansion of highly inbred
744 *Plasmodium vivax* lineages in the main malaria hotspot of Brazil. *PLoS Negl. Trop. Dis.* 14,
745 e0008808 (2020).

746 56. Danecek, P. et al. The variant call format and VCFtools. *Bioinformatics* 27, 2156-2158.

747 57. Purcell, S. et al. PLINK: A tool set for whole-genome association and population-based
748 linkage analyses. *Am. J. Hum. Genet.* 81, 559–575 (2007).

749 58. Csárdi, G. et al. igraph for R: R interface of the igraph library for graph theory and network
750 analysis. R package version 1.3.5 (2022).

751 59. Oksanen, J. et al. vegan: Community Ecology Package. (2022). R package version 2.6-4
752 (2022).

753 60. Natural Earth - free vector and raster map data at 1:10m, 1:50m, and 1:110m scales.
754 Available at <https://www.naturalearthdata.com/> (2024).

755

756

757

758

759

760

Fig. 1








Fig. 2






Fig. 3

a



b








Fig. 4

P. falciparum

P. vivax



Frequency >0.50 IBD
(% sample pairs)



◆ 1

○ 10

○ 30

○ 60

○ 120

Samples
in zone

Fig. 5







Fig. 6



761

762 **Supplementary Text 1**


763 ***Relationships between samples collected in Guyana and Venezuela***

764 We assessed whether our small comparator set from Venezuela (22 monoclonal samples) could
765 indicate the presence of cross-border parasite genetic divergence and transmission of imported
766 strains within Guyana. The Venezuelan comparator set primarily represents infections from the
767 eastern states of Bolívar and Sucre. Two *P. falciparum* samples (PW0065-C and SPT26229)
768 and one *P. vivax* sample (CEM541_Pv-9) lack travel history data. In *P. falciparum*, the IBD
769 distribution for sample-pairs representing comparisons within Guyana (median = 0.283)
770 appeared right-shifted (Wilcoxon test, $W = 57691375$, $p < 0.001$) relative to the IBD distribution
771 for sample-pairs representing cross-border comparisons (median = 0.261, [Supplementary Fig.](#)
772 [9a](#)). To further visualize this divergence signal in *P. falciparum* and to screen for imported
773 transmission, we mapped the highest IBD value observed for each sample with respect to
774 samples representing Venezuela ('MaxVZ', [Supplementary Fig. 9b](#)). Only three infections from
775 Guyana showed aberrant (>2 sd above average) maxVZ. Two of these three (G4G410 and
776 G4G1043) were clonal (>0.90 IBD) with respect to Venezuelan infections Venez_001_F1 and
777 PW0065-C ([Supplementary Fig. 9c,d](#)). Highly aberrant (> 3 sd above average) IBD relative to
778 G4G410 or G4G1043 occurred in five of nine Venezuelan infections but in just one of 527
779 Guyanese samples. These observations suggest that G4G410 and G4G1043 represent cases
780 of imported transmission from Venezuela into Guyana. Observing just two such cases in the
781 sample set suggests that imported transmission is infrequent (despite health posts near the
782 border frequently experiencing foreign cases – see cyan pie slices in [Supplementary Fig. 12](#))
783 but verification is required with larger Venezuelan sample sets.


784 In *P. vivax*, G-G and G-V distributions were also statistically distinguishable ($p < 0.001$) but were
785 very close in absolute overlap (median 0.046 vs. 0.041 (respectively) [Supplementary Fig. 9e](#))).

786 Although scarce, aberrant maxVZ values (>2 sd above average) occurred within Guyana more
787 frequently in *P. vivax* (7/474) than in *P. falciparum* (3/528) and occurred within Venezuela less
788 frequently in *P. vivax* (5/13) than in *P. falciparum* (6/9) ([Supplementary Fig. 9f](#) vs.
789 [Supplementary Fig. 9b](#)).

790 Principal component analysis using direct SNP data (IBS instead of IBD, [Supplementary Fig.](#)
791 [9g](#)) did not help clarify Guyana-Venezuela population patterns in either species. Maps of
792 alternative IBD features (e.g., maximum intrachromosomal IBD tract length) were also difficult to
793 interpret ([Supplementary Fig. 9h-m](#)).





Supplementary Fig. 1 Intra-annual variation in *P. falciparum* and *P. vivax* cases in Guyana. Points represent weekly reported cases and lines represent 30-day rolling averages in 2018 and 2019.


a

Aranka (A)


Serenamu (S)

b

Supplementary Fig. 2 Epidemiological zoning based on connectivity analysis in Guyana. Diagnosis and infection localities (inferred based on reported stay 2 weeks prior to diagnosis) were grouped into 27 epidemiological zones. Though not automated using any fixed thresholds, grouping decisions were partially informed by river distance calculation and resistance surface analysis. a) To measure river distances, localities were first fitted to nearest river coordinates (red and blue points, respectively). Distances along rivers were then measured between assigned coordinates (e.g., Aranka to Serenamu, bottom plot). b) For resistance surface analysis, localities were plotted on a mobility friction map obtained from <https://malariaatlas.org/>. Light grey and white represent highest conductance to motorized travel. The right plot illustrates how a least cost path (black line) inferred for Las Cristinas (Venezuela) to Bartica (Guyana)) matches the flow of the Cuyuni River. Yellow and green represent highest conductance to motorized travel.




Supplementary Fig. 3 Relative *P. falciparum* prevalence with respect to age and gender in Guyana. Boxplots summarize monthly variation (median and quartiles) in the percent of malaria cases representing *P. falciparum* in 2019. Brown and red represent values for male and female cases, respectively.




Supplementary Fig. 4 *P. falciparum* and *P. vivax* case counts by age, gender, and ethnicity in Guyana. Colors in stacked bar charts indicate self-reported ethnicities (key at left) among malaria patients in 2019.

P. falciparum




P. vivax




Supplementary Fig. 5 *P. falciparum* and *P. vivax* pairwise nucleotide diversity among epidemiological zones in Guyana. Boxplots summarize variation (median and quartiles) in windowed π values (y-axis) for each epidemiological zone (x-axis) represented by ≥ 10 genomic samples (see top) in 2020-21.

P. falciparum




P. vivax




Supplementary Fig. 6 *P. falciparum* and *P. vivax* clustering relationships in Guyana and Venezuela. Clusters (circles) represent groups of samples in which each sample is related to at least one other sample in the group at the specified IBD threshold (x-axis, decreasing from left). Circle sizes represent cluster membership sizes, minimally two. Clusters adjacent on the x-axis are connected by a line if the right (lower threshold) cluster contains all the members of the left (higher threshold) cluster. Arrows at left indicate *P. falciparum* clonal group IDs mapped in Supplementary Fig. 8. Analysis includes samples from Guyana (2020-21) and Venezuela (2015-16 and 2019).

a




(Supp. Fig. 7 – continues on next page)


b

Supplementary Fig. 7 Spatiotemporal variation in *P. falciparum* clonal group membership in Guyana. The y-axis lists the clonal groups detected in each epidemiological zone (colors) in 2020-21. Group detection (circle size represents the number of group members detected) is plotted by month on the x-axis. **a)** When detections occur in multiple months per zone, these are connected by black lines. Arrows indicate instances where detection is temporally aggregated, i.e., a 4 month window contains ≥ 3 group members and also represents $>50\%$ of all members within that zone. **b)** In the majority of zones, membership detection does not occur in multiple months. Plots are split into two pages using flipped axes only to fit figure dimensions.

a




(Supp. Fig. 8 – continues on next page)

b

Supplementary Fig. 8 *P. falciparum* clonal group mapping in Guyana and Venezuela. a) Large clonal groups (≥ 10 members each) in 2020-21. **b)** Selected clonal groups highlighted in main text (2015, 2019, and 2020-21). Colors indicate group IDs (key at top left). Star symbols indicate clonal groups with partial membership in Venezuela (#65 in Sucre municipality (2019), Bolívar state, and #20, specific locality unknown (2015)). Semi-transparent symbols indicate the presence of other clonal groups aside than those being highlighted.

a


P. falciparum G-G ———
G-V - - - -



(Supp. Fig. 9 – continues on next pages)

b


P. falciparum maximum genome-wide IBD vs. Venezuelan comparator set (MaxVZ)



(Supp. Fig. 9 – continues on next pages)

C


P. falciparum genome-wide IBD vs. G4G410



(Supp. Fig. 9 – continues on next pages)

d

P. falciparum genome-wide IBD vs. G4G1043




(Supp. Fig. 9 – continues on next pages)

e

P. vivax


G-G ———
G-V - - - -



(Supp. Fig. 9 – continues on next pages)




f

P. vivax maximum genome-wide IBD vs. Venezuelan comparator set (MaxVZ)



(Supp. Fig. 9 – continues on next pages)


g



(Supp. Fig. 9 – continues on next pages)

h


P. falciparum average genome-wide IBD vs. Venezuelan comparator set



(Supp. Fig. 9 – continues on next pages)

i


P. falciparum maximum intra-chromosomal IBD tract length vs. Venezuelan comparator set



(Supp. Fig. 9 – continues on next pages)

j


P. falciparum average intra-chromosomal IBD tract length vs. Venezuelan comparator set



(Supp. Fig. 9 – continues on next pages)


k

P. vivax average genome-wide IBD vs. Venezuelan comparator set




(Supp. Fig. 9 – continues on next pages)

P. vivax maximum intra-chromosomal IBD tract length vs. Venezuelan comparator set




m

P. vivax average intra-chromosomal IBD tract length vs. Venezuelan comparator set




(Supp. Fig. 9 – continues on next page)

Supplementary Fig. 9 Differentiation between Guyanese and Venezuelan *P. falciparum* and *P. vivax* samples. Samples represent 2020-21 (Guyana) and 2015-16 + 2019 (Venezuela). **a)** IBD density curve for *P. falciparum* sample-pairs representing within-Guyana comparisons (G-G, solid line) and Guyana-Venezuela comparisons (G-V, dashed line). **b)** For *P. falciparum*, map of maximum genome-wide IBD vs. any Venezuelan sample (MaxVZ). **c)** For *P. falciparum*, map of genome-wide IBD vs. G4G410 (including comparison of G4G410 to itself (i.e., 100% IBD)). **d)** For *P. falciparum*, map of genome-wide IBD vs. G4G1043 (including comparison of G4G1043 to itself (i.e., 100% IBD)). **e)** IBD density curve for *P. vivax* sample-pairs representing within-Guyana comparisons (G-G, solid line) and Guyana-Venezuela comparisons (G-V, dashed line). **f)** For *P. vivax*, map of maximum genome-wide IBD vs. any Venezuelan sample (MaxVZ). **g)** Principal component analysis in *P. falciparum* (left) and *P. vivax* (right). Sample points plotted on PC1 vs. PC2 are colored according to epidemiological zone, and shape indicates country. All Venezuelan samples are classified to a single zone (yellow triangles). Analysis uses sites with >2% minor allele frequency and no missing genotype calls. **h)** For *P. falciparum*, map of average genome-wide IBD vs. any Venezuelan sample. **i)** For *P. falciparum*, map of maximum intra-chromosomal IBD tract length vs. any Venezuelan sample. **j)** For *P. falciparum*, map of average intra-chromosomal IBD tract length vs. any Venezuelan sample. **k)** For *P. vivax*, map of average genome-wide IBD vs. any Venezuelan sample. **l)** For *P. vivax*, map of maximum intra-chromosomal IBD tract length vs. any Venezuelan sample. **m)** For *P. vivax*, map of average intra-chromosomal IBD tract length vs. any Venezuelan sample. In each map, points are colored based on the standard deviation of the IBD metric from the mean (see color scale at right). Points with higher values are plotted above points with lower values, i.e., are not obscured. Circles represent samples with travel history recorded to the locality level (i.e., using specific coordinates). Squares represent samples with travel history recorded to the municipality level (coordinates are placed within known malaria areas of the municipality (black perimeter)). Travel history for sample CEM526_Pv-2 (diamond) is recorded only to the state level (Barinas (Ba), white perimeter). Its coordinates are placed arbitrarily within Ba. Samples CEM541_Pv-9, PW0065-C, and SPT26229 (triangles and/or text annotation) do not contain any travel history details. Star symbols are used for clonal samples with representation in both Guyana and Venezuela. Municipalities are abbreviated within the Venezuelan states of Bolívar (EC (El Callao), GS (Gran Sabana), He (Heres), Pi (Piar), Sifontes (Sifontes), Su (Sucre)), Sucre (Be (Benítez), Ca (Cajigal), and Ri (Ribero)), and Miranda (Gu (Guaicaipuro)).





Supplementary Fig. 10 *P. falciparum* and *P. vivax* IBD with respect to time difference in sampling dates in Guyana. Boxplots summarize variation (median and quartiles) in time (days) between sampling for different IBD categories (increasing from low to high (clonal) on x-axis) in 2020-21.




Supplementary Fig. 11 Mantel correlograms for *P. falciparum* and *P. vivax* in Guyana. Mantel correlation coefficients (r) are plotted on the y-axis for successive (non-overlapping) spatial distance classes (bars) separating infection localities in 2020-21. Black bars indicate significant r ($p < 0.05$) between genetic and spatial distance matrices. Top plots use 1-p99 IBD frequency and bottom plots use ≤ 0.50 IBD frequency for the genetic distance matrix. Positive r represents isolation-by-distance, i.e., that genetic distance increases with spatial distance.

P. falciparum

P. vivax




cases sampled per epidemiological zone




Infection source
Local
Nonlocal
Foreign import


Case flow (a >>> b)
(# patients representing diagnosis in zone b and prior stay in zone a)




Supplementary Fig. 12 *P. falciparum* and *P. vivax* case flow in Guyana. Pie icon sizes represent the number of cases sampled within each epidemiological zone in 2019. Black slices represent the fraction of cases representing patients that reported having stayed in the same epidemiological zone 2 weeks prior to diagnosis. Grey slices represent the fraction of cases representing patients that reported having stayed in a different epidemiological zone 2 weeks prior to diagnosis. Case flow segments are mapped for such 'non-local' cases. These segments connect the reported location of prior stay with arrows to the location of diagnosis. Arrows are used if the location of diagnosis is considered an endemic zone (e.g., for this reason only solid lines connect to coastal zones around Georgetown). The number of case flow events recorded between zones is represented by segment color, increasing from yellow through orange and red to blue (see scale). The analysis uses 13,641 cases for which information on location of diagnosis and on location 2 weeks prior to diagnosis is available.




Supplementary Fig. 13 Rates of local infection for *P. falciparum* and *P. vivax* in Guyana. For each epidemiological zone (points), the percentage of *P. falciparum* cases representing local infection (x-axis) is plotted against the percentage of *P. vivax* cases representing local infection (y-axis) in 2019. Values correspond to black pie slices in Supplementary Fig. 12. Blue is used when higher values occur for *P. falciparum*, green is used when higher values occur for *P. vivax*, and black is used when values are equal between species.



Supplementary Fig. 14 Relationship between the relative frequency of parasite p99 IBD and patient case flow detected between epidemiological zones in *P. falciparum* and *P. vivax* in Guyana. Genetic data (y-axis) represents 2020-21. Epidemiological (case flow) data (x-axis) represents 2019. Point color indicates the spatial distance separating the zones being compared. Comparisons represented by ≤ 50 comparisons are excluded. Pearson correlation is statistically significant in *P. falciparum* but not in *P. vivax*. Grey shading indicates 95% confidence intervals predicted by linear regression (dashed line).



Supplementary Fig. 15 Linkage decay in *P. falciparum* and *P. vivax* in Guyana. Average linkage values (r^2) between SNP sites are plotted in sliding 10 kbp windows (step size = 200 bp) for samples from 2020-21.



Supplementary Fig. 16 Complexity of infection values for *P. falciparum* and *P. vivax* in Venezuelan and non-Venezuelan patients with infections attributed to NDC VII-2 in Guyana. NDC VII-2 is highlighted in green in the map. Upper plots represent patients of non-Venezuelan nationality and lower plots represent patients of Venezuelan nationality (see large brackets at left). For each malaria species and patient gender, horizontally stacked bars represent complexity of infection (COI) values contributing to total observed polyclonality rate (full length of bar on x-axis) in 2020-21. Orange = 2 strains, yellow = 3 strains, and red = 4 strains. *P. vivax* polyclonality rate is significantly elevated in female Venezuelan patients vs. male Venezuelan patients (Chi-squared test). Differences are non-significant (ns) for other indicated comparisons (see small brackets at right).

VECTOR CONTROL SERVICES - MINISTRY OF PUBLIC HEALTH

M1 (Revised Dec, 2016)

Malaria Daily Case Register (Health Facilities)

Epidemiological week

SAMPLE DATA										
Sample Number:			Locality:				Health Facility:			
Date taken	Region	Case		Detection method			Name (who took sample)			
dd/mm/yyyy		New	Recheck	Passive	Active					
					Mass Blood Survey	Fever Case Survey				
PATIENT DATA										
				Age, yrs	Month: (if < 1 yr)	Sex: M F	Pregnant	N Y	If pregnancy (# Months)	
Current Address	Locality			Region	Nationality					
Ethnic Group (for Guyanese): African Amerindian East Indian Chinese Portuguese European Mixed										
Where patient stayed 2 weeks ago							Symptoms started on			
Locality		Region	Country					dd / mm / yyyy		
Fever:	Current Recent No fever			OTHER SYMPTOM(S)						
LABORATORY TESTS PERFORMED										
RDT: Yes No		Date of RDT: dd / mm / yyyy		RDT Result: Neg (-) Pos (+)		P. vivax/malariae	P. falciparum	Mixed		
Slide	Date of slide	Neg	Pos	P. vivax	P. falciparum		P. malariae	Mixed		
	dd/mm/yyyy	-	+	Plasmodium vivax Density		P. malariae Density		P. falciparum Density		
				Rings Gametes WDC		Rings Gametes WDC		Rings Gametes WDC		
Examination Date:		dd / mm / yyyy		Microscopist Name:						
Treatment started on:		dd / mm / yyyy		# of CoArt	# CQ 150mg	# PQ 15 mg	# PQ 7.5 mg			

CoArt= Coartem; CQ= Chloroquine; WBC= White blood cells; PQ= Primaquine

ALL fields should be filled.

Original (Regional Health Office), Copy (Health Facility); Fever: Current (0 - 5 days), Recent (6 - 30 days), No fever (in the last 31 days).

Supplementary Fig. 17 Malaria case form underlying patient metadata records analyzed from Guyana. Form records of sampling date, sampling location, patient gender, patient age, patient nationality, patient ethnicity, location of patient stay 2 weeks prior to diagnosis, and infecting species (microscopy or RDT result) were provided to study authors using anonymized patient codes. Only cases marked 'New' and 'Passive' were analyzed. The same form was used for 2019 and 2020-21 sample sets.